Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 315.30K | 414.60K | 456.00K | 466.80K | 516.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 315.30K | 414.60K | 456.00K | 466.80K | 516.00K |
| Cost of Revenue | 143.60K | 197.30K | 205.60K | 183.80K | 201.20K |
| Gross Profit | 171.60K | 217.30K | 250.40K | 283.00K | 314.80K |
| SG&A Expenses | 12.19M | 16.37M | 16.44M | 17.77M | 11.80M |
| Depreciation & Amortization | 1.12M | 1.12M | 1.12M | 721.50K | 721.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.46M | 17.69M | 17.77M | 18.68M | 12.72M |
| Operating Income | -13.14M | -17.27M | -17.32M | -18.21M | -12.21M |
| Income Before Tax | -15.10M | -19.21M | -20.64M | -19.82M | -14.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.10 | -19.21 | -20.64 | -19.82 | -14.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 700.00 | 400.00 | 500.00 | 900.00 | 800.00 |
| Net Income | -15.10M | -19.21M | -20.64M | -19.82M | -14.20M |
| EBIT | -13.14M | -17.27M | -17.32M | -18.21M | -12.21M |
| EBITDA | -12.08M | -15.67M | -15.59M | -16.22M | -10.23M |
| EPS Basic | -1.22 | -1.70 | -2.59 | -3.12 | -3.57 |
| Normalized Basic EPS | -0.66 | -0.94 | -1.47 | -1.87 | -2.07 |
| EPS Diluted | -1.22 | -1.70 | -2.59 | -3.12 | -3.57 |
| Normalized Diluted EPS | -0.66 | -0.94 | -1.47 | -1.87 | -2.07 |
| Average Basic Shares Outstanding | 59.31M | 52.18M | 40.29M | 28.72M | 19.21M |
| Average Diluted Shares Outstanding | 59.31M | 52.18M | 40.29M | 28.72M | 19.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |